Navigation Links
Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
Date:9/23/2010

o TAXUS (7.4 percent for XIENCE V vs. 11.4 percent for TAXUS, p-value=0.0038).

In addition, XIENCE V demonstrated a 77 percent lower rate of stent thrombosis, defined as definite or probable according to ARC (0.9 percent for XIENCE V vs. 3.9 percent for TAXUS, p-value=<0.0001); a 60 percent lower rate of TVR (3.1 percent for XIENCE V vs. 7.7 percent for TAXUS, p-value=<0.0001); a 56 percent lower rate of TLR (2.6 percent XIENCE V vs. 5.9 percent TAXUS, p-value=0.0005); and a 49 percent lower rate of non-fatal MI (3.9 percent XIENCE V for vs. 7.6 percent for TAXUS, p-value=0.0009).

The stent thrombosis rate for XIENCE V between one and two years increased from 0.7 percent at one year to 0.9 percent at two years, while the TAXUS arm increased from 2.6 percent at one year to 3.9 percent at two years. At two years, 88.6 percent of XIENCE V patients and 84.8 percent of TAXUS patients had discontinued dual-antiplatelet therapy.

"The COMPARE results show that the gap in stent thrombosis rates between XIENCE V and TAXUS Liberte widened from 1.9 percent at one year to 3.0 percent at two years," said Charles A. Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. "The COMPARE investigators have provided some of the first major insights into the comparative long-term differences in stent thrombosis rates between one and two years for different stent platforms."

"The two-year results presented today for the COMPARE trial and for the SPIRIT IV trial demonstrate impressive outcomes for XIENCE V compared to TAXUS Liberte and TAXUS Express, respectively," said Robert Hance, senior vice president, vascular, Abbott. "Both of these trials show the differences in the performance of these drug eluting stents and add to the ever-growing body of safety and efficacy data for XIENCE V – reinforcing why XIENCE V continues to be the market-leading drug eluting stent."

About The
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
2. New Data Reinforces Safety Profile of Abbotts Market-Leading XIENCE V(R) Drug Eluting Stent
3. Abbotts XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
4. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
5. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
6. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
7. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
8. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
9. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
10. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
11. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015 /PRNewswire/ ... devices are artificial implants used to replace, augment, ... used in a wide range of applications including ... These implants are made of different materials such ... analysts forecast the global implantable medical devices market ...
(Date:9/2/2015)... -- About Neuroendovascular Coil A ... and ruptured brain aneurysm (a weakened area in ... as an endovascular coiling or endovascular embolization. During ... flow in an aneurysm. The endovascular coiling treatment ... interventional neuroradiologist using fluoroscopic imaging guidance. Neuroendovascular coils ...
(Date:9/2/2015)... -- About Chronic Lymphocytic Leukemia Chronic ... production of lymphocytes. It has been observed that the ... to other parts of the body. This leukemia is ... buildup of the cancerous cells. During the course of ... and lymph nodes. The course of the disease is ...
Breaking Medicine Technology:Global Implantable Medical Devices Market 2015-2019 2Global Neuroendovascular Coil Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3
...  Premier Research Group announces the appointment of Susan ... Vice President, Clinical Development. In this position, Dr. ... developing the company,s clinical trial management services provided ... industry knowledge and proven leadership skills will be ...
...  LIQUENT, Inc. the global leader in regulatory information ... LIQUENT,s XEVMPD Educational Series and Data Assessment tool. ... the July 2012 deadline for submitting product information ... LIQUENT,s XEVMPD Educational Series is ...
Cached Medicine Technology:Premier Research Names Susan Stansfield, PhD Executive VP, Clinical Development 2LIQUENT Announces XEVMPD Educational Series and Data Assessment Tool 2
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... robust distribution channels and efficient customer and technical support services to promote LodonalTM ... approved 90-day Bridging trial evaluating the efficacy and safety of the product. , ...
(Date:9/2/2015)... ... September 03, 2015 , ... Leah Binder, MA, MGA, ... influential leaders in healthcare, will offer the keynote address at the upcoming meeting ... 2015, in Palm Harbor, Florida, at the Innisbrook Resort and Golf Club. For ...
(Date:9/2/2015)... Washington, DC (PRWEB) , ... September 03, 2015 ... ... stacks of nominations to determine who among America’s policymakers, public servants, activists, corporate ... on the nation’s health care. This year, that process led the magazine to ...
(Date:9/2/2015)... (PRWEB) , ... September 02, ... ... the 2015 Warrior-Family Symposium (WFS), cosponsored by the Military Officers Association of ... During the event, "Our Nation's Military: Caring For Our Own,” expert panelists ...
(Date:9/2/2015)... Los Angeles, CA (PRWEB) , ... September 02, 2015 , ... ... working to expand their fleet of truly superb luxury vehicles based on which of ... are pleased to announce the latest step forward in pursuit of this goal: a ...
Breaking Medicine News(10 mins):Health News:Fidson Partners US Firms on New Product Marketing 2Health News:Fidson Partners US Firms on New Product Marketing 3Health News:Fidson Partners US Firms on New Product Marketing 4Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2
... with demand. Two experts in this weeks BMJ debate whether ... there is evidence to the contrary is the answer. ... support organ donation, yet only 23% have registered their wish ... at the British Medical Association. ,Research indicates that ...
... robotic technology may improve survival rates for prostate ... Thomas Jefferson University Hospitals multidisciplinary Genitourinary (GU) cancer ... 21, 2007 at the annual American Urological Society ... that performing a laparoscopic radical prostatectomy (LRP) with ...
... 10-fold over the past 40 years in England, owing to ... finds research published ahead of print in the British ... wide geographical variation in rates suggest that the NHS is ... and training, say the authors. ,The research team ...
... Researchers at Jefferson Medical College have shown that capsule ... small bowel Crohns disease in children. The technology has ... more than five years to diagnose unexplained abdominal bleeding ... is not much bigger than a vitamin pill and ...
... In a move to improve global public health, Weill ... heart disease drug onto the World Health Organization's ... guideline for developing countries to choose which high-priority drugs ... ,Students from Weill Cornell's chapter of Universities Allied for ...
... young to speak or crawl, but they can certainly tell ... with only visual cues. ,Researcher Whitney Weikum ... able to discern when a different language is spoken by ... face movements. ,The findings suggest that babies growing ...
Cached Medicine News:Health News:Is Presumed Consent the Answer to Organ Shortages? 2Health News:Robotic Surgery May Improve Survival Rate For Prostate Cancer Patients 2Health News:NHS Oversupplied With Cataract Surgery, Say Doctors 2Health News:Medical College Students Help Change Global Health Policy 2Health News:Even at Four Months, Babies can Tell When Speakers Switch Languages 2
Diareader ELX800G...
Plate Reader is an eight channel photometer for the sequential and simultaneous reading of micro-plate strips with 96 wells. High technology, user friendly, powerful and reliable....
... certified microstrip reader. Stat fax 303 ... to use with step-by-step prompting and ... other programming enhancements. On-board software calculates ... & a variety of cutoff options. ...
Iems Incubator/Shaker expansion module for 2 module incubator/shaker. high performance microplate incubator and orbital shaker. It's superior temperature control and efficient orbital shaking reduce ...
Medicine Products: